But the FDA’s decision does not preclude CMS from determining that the higher dose is not reasonable and necessary — ...
Advances in cancer treatment mean that more people than ever are surviving the disease. However, some of the most effective ...
Medicare Part D, an optional component of Medicare, helps beneficiaries pay for generic and name-brand prescription drugs. A Low Income Subsidy (LIS) can provide financial support to enrollees with ...
Researchers have developed a light-activated nanoassembly that helps anticancer drugs overcome multiple intracellular barriers and reach the cell nucleus more efficiently. This strategy significantly ...
BRCA1 and BRCA2 genes play a crucial role in repairing damaged DNA. Mutations in BRCA1 and BRCA2 substantially increase the likelihood of breast and ovarian cancer, respectively. This new research ...
A one‑year course of T‑DM1 offers excellent cancer‑free survival for early HER2‑positive breast cancer, with far less nerve ...
CHICAGO, IL / ACCESS Newswire / January 22, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in ...
Launch prices for Medicare Part D anticancer drugs have risen sharply since 2012, with a mean increase of $1694 per year. In 2025, the observed prices were 15%-200% higher than expected if the ...
Researchers have developed a human intestinal cell model that closely mimics the structure and function of the human gut, enabling more precise prediction of drug-induced gastrointestinal toxicity ...
The latest map of all the genes involved in a set of tumor cells exposes which mutations drive cancer and how to possibly treat them. The Human Genome Project provided the first glimpse of the power ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results